ARTICLE | Company News
Neurocrine, GlaxoSmithKline deal
November 5, 2001 8:00 AM UTC
NBIX received a $15.5 million milestone from GSK, the first under the companies' July deal to develop and market corticotropin releasing factor receptor antagonists (CRF-R1 and CRF-R2) to treat psychi...